Login to Your Account

Exelixis, BMS Cancer Deal Valued As High As $120M

By Randall Osborne

Tuesday, December 19, 2006
Exelixis Inc.'s potential $120 million deal for cancer drugs with Bristol-Myers Squibb Co. broadens the two firms' longstanding relationship in oncology, providing $60 million up front while letting Exelixis keep sole ownership of a substantial pipeline. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription